Clinical research in the older cancer patient. [Review]. 
Muss HB, Cohen HJ, Lichtman SM. Hematology - Oncology Clinics of North America. 2000;14:283-91.

The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont. 
Lam PB, Vacek PM, Geller BM, Muss HB. Cancer. 2000;89:369-75.

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. 
Berry DA, Muss HB, Thor AD, et al. Journal of Clinical Oncology. 2000;18:3471-9.

American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. 
Smith TJ, Davidson NE, Schapira DV, et al. Journal of Clinical Oncology. 1999;17:1080-2.

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. 
Abrams J, Aisner J, Cirrincione C, et al. Journal of Clinical Oncology. 1999;17:64-73.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer [see comments]. 
Thor AD, Berry DA, Budman DR, et al. Journal of the National Cancer Institute. 1998;90:1346-60.

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B [see comments]. 
Budman DR, Berry DA, Cirrincione CT, et al. Journal of the National Cancer Institute. 1998;90:1205-11.

Hormonal therapy of breast cancer: state of the art. [Review]. 
Murphy B, Muss HB. Oncology (Huntington). 1997;11:7-13.

Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. 
Kuss JT, Muss HB, Hoen H, Case LD. Breast Cancer Research & Treatment. 1997;42:265-74.

Cancer chemotherapy in older adults. A tolerability perspective. [Review]. 
Kimmick GG, Fleming R, Muss HB, Balducci L. Drugs & Aging. 1997;10:34-49.

Breast cancer in older women. [Review]. 
Kimmick G, Muss HB. Clinics in Geriatric Medicine. 1997;13:265-82.

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. 
Chan DW, Beveridge RA, Muss H, et al. Journal of Clinical Oncology. 1997;15:2322-8.